Core Products

A once-daily dose of type 2 diabetes treatment pioglitazone hydrochloride improves insulin sensitivity and reduces blood glucose levels, without placing an additional burden on the pancreas. The drug is marketed in around 90 countries worldwide. It is also marketed in a fixed-dose combination with metformin, as well as a fixed-dose combination with glimepiride.

Originally discovered by Takeda San Diego, Inc., this type 2 diabetes treatment alogliptin benzoate has a novel mechanism of action. It lowers blood glucose levels by inhibiting an enzyme (DPP-4) that breaks down glucagon-like peptide-1 (GLP-1), a hormone that stimulates secretion of insulin.

Candesartan cilexetil is an angiotensin II receptor blocker* (ARB) for hypertension treatment. A once-daily dosing provides patients with a long lasting mild anti-hypertensive effect. Candesartan cilexetil is marketed in around 100 countries worldwide, and enjoys a trusted reputation in the medical profession in each country. Candesartan cilexetil also has an indication for the treatment of chronic heart failure. In addition, a fixed-dose combination with a diuretic agent is also marketed in around 60 countries for hypertension.

• * Angiotensin II receptor blocker: blocks the action of angiotensin II, a hormone that increases blood pressure.

Azilsartan is a new angiotensin II receptor blocker (ARB). It has demonstrated superior efficacy in lowering blood pressure over previous ARBs in clinical trials.

Ramelteon has a different mechanism of action to conventional insomnia treatments. It acts on melatonin* receptors to induce a state close to physiologically natural sleep. Since the drug promotes sleep without needing to suppress anxiety or sedate, the user it is expected to show an established safety profile.

• * Melatonin is the hormone that induces sleep; it regulates the circadian rhythms that govern when we sleep and wake.

In-licensed from Janssen Pharmaceutical, galantamine hydrobromide is considered one of the standard treatments for Alzheimer's-type dementia outside of Japan. Used in over 70 countries around the world while launched in Japan in 2011, it is the first new treatment in this therapeutic field in Japan in about 10 years.

Roflumilast is a first-in-class oral phosphodiesterase-4 (PDE-4) inhibitor.It is not a steroid and has anti-inflammatory action in the whole body or lungs related to chronic obstructive pulmonary disease (COPD).

Discovered by Teijin Pharma Limited, febuxostat is a treatment for hyperuricemia in patients with gout. It lowers the level of uric acid in the blood of hyperuricemic patients with gout by blocking the enzyme that is responsible for the synthesis of uric acid.

Colchicine is the only colchicine formulation approved by the U.S. Food and Drug Administration (FDA). It has been used for centuries as a highly effective treatment for gout, and URL Pharma received approval to market it in 2009 following completion of an extensive clinical development program to allow safer and more convenient use of the drug.

Discovered by Millennium, bortezomib is the only drug for treating multiple myeloma (MM) that has overall survival benefit data included in its prescribing information in the U.S. Approved in more than 90 countries around the world, it is indicated in Europe and the U.S. as a first-line treatment for MM patients that have not undergone chemotherapy.

Leuprorelin acetate is an LH-RH agonist with a sustained-release formulation to which we devoted the results of our drug delivery system (DDS) research. It is marketed in around 80 countries worldwide and is considered a gold standard therapy for prostate cancer. Its sustained-release injectable formulation, available up to once every six months, has also been marketed in Europe.

In-licensed from Amgen Inc., panitumumab is an anti-EGFR human monoclonal antibody* that inhibits epidermal growth factor receptors (EGFR). Inhibiting EGFR function suppresses tumor growth.

• * A genetically engineered artificial human antibody, which selectively targets cancer cells and stimulates the immune system.

A once-daily dosing with lansoprazole, a proton pump* inhibitor, provides fast symptom relief for gastric and duodenal ulcers, and achieves high healing rates. Lansoprazole is marketed in around 90 countries worldwide and has won an excellent reputation in each country.

• * Proton pump: an enzyme that functions in the final stages of acid secretion in gastric pariental cells.

Dexlansoprazole is the first proton pump inhibitor specifically designed for the release of medicine in two stages over time. It has a powerful and sustained suppressant effect on gastric acid secretion.

Peginesatide is an erythropoiesis-stimulating agent (ESA) for the treatment of anemia in adult patients on dialysis. It is the first ESA formulation in the U.S. to be approved for once monthly dosing.